Heyi Pharmaceutical releases a performance brief, reporting that in 2025 the company achieved operating revenue of 288 million yuan, a year-on-year increase of 6.37%; net profit of 50.33 million yuan, up 1.34%; and net profit excluding non-recurring gains and losses of 47.39 million yuan, an increase of 4.74%. During the reporting period, the company continued to deepen its business layout and market development, actively responded to external environmental changes, steadily expanded market share, optimized product sales structure, and effectively enhanced market competitiveness and overall profitability.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Heyi Pharmaceutical: Net profit of 50.33 million yuan in 2025, a year-on-year increase of 1.34%
Heyi Pharmaceutical releases a performance brief, reporting that in 2025 the company achieved operating revenue of 288 million yuan, a year-on-year increase of 6.37%; net profit of 50.33 million yuan, up 1.34%; and net profit excluding non-recurring gains and losses of 47.39 million yuan, an increase of 4.74%. During the reporting period, the company continued to deepen its business layout and market development, actively responded to external environmental changes, steadily expanded market share, optimized product sales structure, and effectively enhanced market competitiveness and overall profitability.